Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

ClinicalTrials.gov ID: NCT06384261

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06384261. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine?

Study identification

NCT ID
NCT06384261
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
OncoVerity, Inc.
Industry
Enrollment
140 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 22, 2024 (Actual)
Primary completion
Jan 2027 (Estimated)
Completion
Jun 2027 (Estimated)
Last update posted
May 11, 2026

2024 – 2027

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Banner MD Anderson Gilbert Arizona 85234 —
City of Hope Duarte California 91010 —
University of California Los Angeles Los Angeles California 90095 —
University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus Aurora Colorado 80045 —
Yale School of Medicine New Haven Connecticut 06510 —
University of Miami - Sylvester Comprehensive Cancer Center - Miami Miami Florida 33136 —
AdventHealth Medical Group Blood & Marrow Transplant at Orlando Orlando Florida 32804 —
University of South Florida = Moffitt Cancer Center and Research Institute Tampa Florida 33612 —
The University of Iowa Hospitals & Clinics Iowa City Iowa 52242 —
University of Kentucky Chandler Medical Center Lexington Kentucky 40536 —
Norton Healthcare, Inc. Louisville Kentucky 40202 —
Hackensack University Medical Center Hackensack New Jersey 07601 —
Hofstra/Northwell Health Lake Success New York 11042 —
Cornell University New York New York 10065 —
University of Rochester Medical Center Rochester New York 14642 —
Wake Forest North Carolina Winston-Salem North Carolina 27157 —
Cleveland Clinic - Taussig Cancer Institute Cleveland Ohio 44195 —
Medical University of South Carolina Charleston South Carolina 29425 —
Fred Hutch Seattle Cancer Care Alliance Seattle Washington 98109 —
Medical College of Wisonsin Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06384261, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 11, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.